NL - ProFibrix closes $11m Series A financing round

ProFibrix BV, a Leiden-based biotech company focused on products to stop bleeding and initiate tissue repair, has closed a Series A financing round raising $11m. The round was led by Index Ventures and backed by some of the current share holders of ProFibrix. It was also announced that Dr. Bram Bout, who previously held the position of VP protein production at Crucell and has approximately 15 years experience in the biopharmaceutical industry, has joined ProFibrix as of 1 April 2007 as chief technology officer.